被検体画像の順列を用いた種子ベースのdマッピングを用いたボクセルベース神経イメージング研究のメタ分析(SDM-PSI)

Executive Industry Relevance

In neuropharmacology and CNS drug development, reconciling contradictory neuroimaging findings is critical for target validation and mechanistic de-risking. SDM-PSI advances beyond binary significance testing by quantifying effect strength and assessing bias, enabling more confident go/no-go decisions in early discovery. This supports portfolio triage by providing continuous evidence grading rather than binary outcomes.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by assessing whether observed neuroimaging effects are non-null rather than merely counting significant peaks.
• Operational Value: Enables pathway clarification through effect size estimation and bias detection, reducing false target assumptions.
• Predictive Value: Supports predictive confidence by grading evidence strength across significance levels and data quantity, informing target prioritization.

Screening & Assay Development

• Assay Readiness: Prepares validated neuroimaging biomarkers for downstream screening by establishing reproducible effect maps with quantified uncertainty.
• Quantitative Outputs: Generates continuous effect size estimates (d-values) and heterogeneity metrics (I-squared) that enable reliable compound screening decisions.
• Platform Reuse: Standardized workflow supports cross-modality application (fMRI, VBM, DTI, PET) for consistent biomarker validation across discovery campaigns.

Translational & Preclinical Research

• Translational Continuity: Bridges discovery and preclinical validation by providing disease-relevant effect maps with bias assessment, supporting mechanistic de-risking.
• Risk-Adjusted Advancement: Evidence grading criteria (incorporating significance levels, data amount, small-study effect, excess significance) inform preclinical go/no-go decisions.
• Biomarker Alignment: Enables alignment of imaging biomarkers with phenotypic outcomes through spatially specific, bias-corrected effect maps.

Pipeline & Workflow Integration

SDM-PSI integrates into the discovery continuum from target validation through lead identification to preclinical work by providing quantitative, bias-aware neuroimaging evidence that supports hypothesis testing and mechanistic de-risking.

• Discovery Biology: Supports hypothesis testing by assessing non-null effects and estimating effect sizes, moving beyond peak counting to biological effect quantification.
• Screening: Delivers assay-ready, reproducible effect maps with quantitative outputs (T-values, d-values, P-values) enabling reliable compound evaluation across modalities.
• Analytics: Provides statistical outputs including heterogeneity (I-squared), bias tests (funnel plot, excess significance), and graded evidence levels for cross-functional interpretation.
• Translational Research: Connects to preclinical continuity through disease-relevant effect maps (e.g., OCD gray matter volume) with quantified uncertainty and bias assessment.
• Enterprise Reuse: Establishes a reusable neuroimaging meta-analysis platform applicable across psychiatric indications and imaging modalities, reducing redundant method development.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence through effect size estimation, target validation via non-null effect assessment, reduction of mechanistic ambiguity by quantifying biological effects.
• Operational Value: Standardization via predefined preprocessing and analysis pipelines, reproducibility through permutation-based inference, scalability across studies and modalities.
• Strategic Value: Better go/no-go decisions via evidence grading, capital efficiency by reducing false target pursuit, reduced late-stage biological risk through early bias detection.
• Portfolio Impact: Risk-adjusted prioritization using graded evidence (significance levels, data amount, bias detection), advancement decisions informed by continuous effect metrics.

Implementation Considerations

• Expertise in neuroimaging meta-analysis, statistical interpretation of permutation tests, and understanding of bias assessment methods (funnel plots, excess significance tests).
• SDM-PSI software infrastructure, capacity for permutation testing (hours/days per analysis), and visualization tools (MRIcron) for result interpretation.
• Cross-team standardization of inclusion/exclusion criteria, data extraction protocols (converting Z/P to T-values), and stereotactic space reporting (MNI/Talairach).
• Adaptation considerations across neuroimaging modalities (fMRI, VBM, DTI, PET, SBM) requiring modality-specific preprocessing in SDM-PSI.
• Practical limitations include dependence on primary study quality, potential bias from unpublished null results, and computational demands of permutation testing for large datasets.

Biopharma FAQs